glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and
Description
P =0.05), ovarian (HR 0.53
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40842-026-00295-3/MediaObjects/40842_2026_295_Figa_HTML.png)
Wang Z, Zhao Y, Zhang L
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://www.ahajournals.org/cms/10.1161/CIRCULATIONAHA.122.059595/asset/ad09f9fb-0bf4-4c02-8c15-fe4df1f5a441/assets/graphic/circulationaha.122.059595.fig01.jpg)
Materials and Methods The systematic review encompasses 51 studies comprising 22 case studies, 2 clinical trials, 2 cohort studies, 10 systematic reviews and meta-analyses, 2 scoping reviews, and 13 narrative reviews
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://revolutionhealth.org/cdn/shop/articles/NAION_Study_GLP-1_Eye_Problems.png?v=1770058788&width=1100)
GLP-1 receptor agonist 2
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12170-025-00761-0/MediaObjects/12170_2025_761_Fig1_HTML.png)
Retrieved 3 October 2025
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://www.aoa.org/AOA/Images/News_2025/WIF_GLP1_1600x800_v1.png)
The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] The long-term cardiovascular safety and](https://www.mdpi.com/diabetology/diabetology-06-00117/article_deploy/html/images/diabetology-06-00117-g001.png)